Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS.

NPJ Precis Oncol. 2019 Aug 29;3:21. doi: 10.1038/s41698-019-0093-2. eCollection 2019.

2.

High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes.

Singh M, Al-Eryani G, Carswell S, Ferguson JM, Blackburn J, Barton K, Roden D, Luciani F, Giang Phan T, Junankar S, Jackson K, Goodnow CC, Smith MA, Swarbrick A.

Nat Commun. 2019 Jul 16;10(1):3120. doi: 10.1038/s41467-019-11049-4.

3.

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.

Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken RS, Nguyen TV, Oyajobi BO, Aftab D, Swarbrick A, Parker B, Hewett DR, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI.

Blood. 2019 Jul 4;134(1):30-43. doi: 10.1182/blood.2018880930. Epub 2019 Apr 25.

PMID:
31023703
4.

Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E.

Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333.

PMID:
30557851
5.

Epigenomics of mammary gland development.

Holliday H, Baker LA, Junankar SR, Clark SJ, Swarbrick A.

Breast Cancer Res. 2018 Sep 3;20(1):100. doi: 10.1186/s13058-018-1031-x. Review.

6.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A.

Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6.

7.

A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes.

Papachristou EK, Kishore K, Holding AN, Harvey K, Roumeliotis TI, Chilamakuri CSR, Omarjee S, Chia KM, Swarbrick A, Lim E, Markowetz F, Eldridge M, Siersbaek R, D'Santos CS, Carroll JS.

Nat Commun. 2018 Jun 13;9(1):2311. doi: 10.1038/s41467-018-04619-5.

8.

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.

Lin HM, Nikolic I, Yang J, Castillo L, Deng N, Chan CL, Yeung NK, Dodson E, Elsworth B, Spielman C, Lee BY, Boyer Z, Simpson KJ, Daly RJ, Horvath LG, Swarbrick A.

Sci Rep. 2018 May 18;8(1):7820. doi: 10.1038/s41598-018-26050-y.

9.

MASTL overexpression promotes chromosome instability and metastasis in breast cancer.

Rogers S, McCloy RA, Parker BL, Gallego-Ortega D, Law AMK, Chin VT, Conway JRW, Fey D, Millar EKA, O'Toole S, Deng N, Swarbrick A, Chastain PD, Cesare AJ, Timpson P, Caldon CE, Croucher DR, James DE, Watkins DN, Burgess A.

Oncogene. 2018 Aug;37(33):4518-4533. doi: 10.1038/s41388-018-0295-z. Epub 2018 May 10.

10.

GPR65 inhibits experimental autoimmune encephalomyelitis through CD4+ T cell independent mechanisms that include effects on iNKT cells.

Wirasinha RC, Vijayan D, Smith NJ, Parnell GP, Swarbrick A, Brink R, King C, Stewart G, Booth DR, Batten M.

Immunol Cell Biol. 2018 Feb;96(2):128-136. doi: 10.1111/imcb.1031. Epub 2017 Dec 19.

PMID:
29363187
11.

Discovering cancer vulnerabilities using high-throughput micro-RNA screening.

Nikolic I, Elsworth B, Dodson E, Wu SZ, Gould CM, Mestdagh P, Marshall GM, Horvath LG, Simpson KJ, Swarbrick A.

Nucleic Acids Res. 2017 Dec 15;45(22):12657-12670. doi: 10.1093/nar/gkx1072.

12.

Toxic shock syndrome: A dermatological emergency.

Swarbrick AW, Kumarasinghe SP.

Australas J Dermatol. 2018 May;59(2):154-155. doi: 10.1111/ajd.12730. Epub 2017 Sep 27. No abstract available.

PMID:
28960233
13.

Congenital Herpes Simplex Virus Type 1 Infection Mimicking Congenital Erosive and Vesicular Dermatosis: Possible Pathogenic Insights.

Swarbrick AW, Blyth CC, Halbert AR.

Pediatr Dermatol. 2017 Jul;34(4):e168-e170. doi: 10.1111/pde.13166. Epub 2017 May 25.

PMID:
28543846
14.

The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior.

Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Köhler M, Halbach S, Becker AC, Deng N, Schmitz T, Uhl FM, Herbener N, Riedel B, Beier F, Swarbrick A, Lassmann S, Dengjel J, Zeiser R, Brummer T.

EBioMedicine. 2017 Jun;20:79-97. doi: 10.1016/j.ebiom.2017.04.015. Epub 2017 Apr 12.

15.

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.

Lin HM, Mahon KL, Spielman C, Gurney H, Mallesara G, Stockler MR, Bastick P, Briscoe K, Marx G, Swarbrick A, Horvath LG.

Br J Cancer. 2017 Apr 11;116(8):1002-1011. doi: 10.1038/bjc.2017.50. Epub 2017 Mar 9.

16.

Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.

Sax MJ, Gasch C, Athota VR, Freeman R, Rasighaemi P, Westcott DE, Day CJ, Nikolic I, Elsworth B, Wei M, Rogers K, Swarbrick A, Mittal V, Pouliot N, Mellick AS.

Oncotarget. 2016 Dec 20;7(51):85437-85449. doi: 10.18632/oncotarget.13387.

17.

ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.

Baker LA, Holliday H, Swarbrick A.

Endocr Relat Cancer. 2016 Sep;23(9):R381-92. doi: 10.1530/ERC-16-0196. Epub 2016 Jul 13. Review.

PMID:
27412917
18.

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.

Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora F, Herrmann D, Salomon R, Young AI, Lee BY, Sergio CM, Kaplan W, Piggin C, Conway JR, Rabinovich B, Millar EK, Oakes SR, Chtanova T, Swarbrick A, Naylor MJ, O'Toole S, Green AR, Timpson P, Gee JM, Ellis IO, Clark SJ, Ormandy CJ.

PLoS Biol. 2015 Dec 30;13(12):e1002330. doi: 10.1371/journal.pbio.1002330. eCollection 2015 Dec.

19.

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.

Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O'Toole SA.

Histopathology. 2016 Jul;69(1):25-34. doi: 10.1111/his.12904. Epub 2016 Jan 13.

PMID:
26588661
20.

MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer.

Gee HE, Buffa FM, Harris AL, Toohey JM, Carroll SL, Cooper CL, Beith J, McNeil C, Carmalt H, Mak C, Warrier S, Holliday A, Selinger C, Beckers R, Kennedy C, Graham P, Swarbrick A, Millar EK, O'Toole SA, Molloy T.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1104-14. doi: 10.1016/j.ijrobp.2015.08.046. Epub 2015 Sep 3.

PMID:
26581147
21.

MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene.

Phua YW, Nguyen A, Roden DL, Elsworth B, Deng N, Nikolic I, Yang J, Mcfarland A, Russell R, Kaplan W, Cowley MJ, Nair R, Zotenko E, O'Toole S, Tan SX, James DE, Clark SJ, Kouros-Mehr H, Swarbrick A.

Breast Cancer Res. 2015 Jun 13;17:83. doi: 10.1186/s13058-015-0593-0.

22.

ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype.

Junankar S, Baker LA, Roden DL, Nair R, Elsworth B, Gallego-Ortega D, Lacaze P, Cazet A, Nikolic I, Teo WS, Yang J, McFarland A, Harvey K, Naylor MJ, Lakhani SR, Simpson PT, Raghavendra A, Saunus J, Madore J, Kaplan W, Ormandy C, Millar EK, O'Toole S, Yun K, Swarbrick A.

Nat Commun. 2015 Mar 27;6:6548. doi: 10.1038/ncomms7548.

PMID:
25813983
23.

Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer.

Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, McKenna CE, Croucher PI, Swarbrick A, Weilbaecher K, Phan TG, Rogers MJ.

Cancer Discov. 2015 Jan;5(1):35-42. doi: 10.1158/2159-8290.CD-14-0621. Epub 2014 Oct 13.

24.

Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.

Ali NA, Wu J, Hochgräfe F, Chan H, Nair R, Ye S, Zhang L, Lyons RJ, Pinese M, Lee HC, Armstrong N, Ormandy CJ, Clark SJ, Swarbrick A, Daly RJ.

Breast Cancer Res. 2014 Sep 9;16(5):437. doi: 10.1186/s13058-014-0437-3.

25.

Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer.

Owens TW, Rogers RL, Best S, Ledger A, Mooney AM, Ferguson A, Shore P, Swarbrick A, Ormandy CJ, Simpson PT, Carroll JS, Visvader J, Naylor MJ.

Cancer Res. 2014 Sep 15;74(18):5277-5286. doi: 10.1158/0008-5472.CAN-14-0053. Epub 2014 Jul 23.

26.

Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.

Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, Liu B, Bell JL, Zhang XD, Milazzo G, Cheung BB, Fox A, Swarbrick A, Hüttelmaier S, Kavallaris M, Perini G, Mattick JS, Dinger ME, Liu T.

J Natl Cancer Inst. 2014 Jun 6;106(7). pii: dju113. doi: 10.1093/jnci/dju113. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2015 Jan;107(1):doi/10.1093/jnci/dju359.

27.

ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities.

Nair R, Teo WS, Mittal V, Swarbrick A.

Mol Ther. 2014 Aug;22(8):1407-1415. doi: 10.1038/mt.2014.83. Epub 2014 May 14. Review.

28.

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.

Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG.

Br J Cancer. 2014 May 13;110(10):2462-71. doi: 10.1038/bjc.2014.181. Epub 2014 Apr 8.

29.

New insights into the role of ID proteins in breast cancer metastasis: a MET affair.

Teo WS, Nair R, Swarbrick A.

Breast Cancer Res. 2014 May 15;16(2):305. doi: 10.1186/bcr3654.

30.

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?

Swarbrick A, Junankar SR, Batten M.

Oncoimmunology. 2013 Aug 1;2(8):e25409. Epub 2013 Jul 1.

31.

c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.

Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O'Toole SA, Swarbrick A.

Oncogene. 2014 Jul 24;33(30):3992-4002. doi: 10.1038/onc.2013.368. Epub 2013 Sep 23.

PMID:
24056965
32.

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.

Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.

J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.

33.

Interleukin-27 signaling promotes immunity against endogenously arising murine tumors.

Natividad KD, Junankar SR, Mohd Redzwan N, Nair R, Wirasinha RC, King C, Brink R, Swarbrick A, Batten M.

PLoS One. 2013;8(3):e57469. doi: 10.1371/journal.pone.0057469. Epub 2013 Mar 12.

34.

The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy.

Hui M, Cazet A, Nair R, Watkins DN, O'Toole SA, Swarbrick A.

Breast Cancer Res. 2013 Mar 28;15(2):203. doi: 10.1186/bcr3401. Review.

35.

Therapeutic targets in triple negative breast cancer.

O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A, Oakes SR.

J Clin Pathol. 2013 Jun;66(6):530-42. doi: 10.1136/jclinpath-2012-201361. Epub 2013 Feb 22. Review.

PMID:
23436929
36.

Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway.

Croucher DR, Hochgräfe F, Zhang L, Liu L, Lyons RJ, Rickwood D, Tactacan CM, Browne BC, Ali N, Chan H, Shearer R, Gallego-Ortega D, Saunders DN, Swarbrick A, Daly RJ.

Cancer Res. 2013 Mar 15;73(6):1969-80. doi: 10.1158/0008-5472.CAN-12-1472. Epub 2013 Feb 1.

37.

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ.

PLoS Biol. 2012;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27.

38.

Nurse accreditation: a better way of working.

Swarbrick A.

J Fam Plann Reprod Health Care. 2013 Jan;39(1):67. doi: 10.1136/jfprhc-2012-100488. Epub 2012 Oct 30. No abstract available.

39.

New insights into signalling networks regulating breast cancer stem cells.

Swarbrick A, Daly RJ.

Breast Cancer Res. 2012 Sep 21;14(5):321. doi: 10.1186/bcr3209.

40.

MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells.

Plummer PN, Freeman R, Taft RJ, Vider J, Sax M, Umer BA, Gao D, Johns C, Mattick JS, Wilton SD, Ferro V, McMillan NA, Swarbrick A, Mittal V, Mellick AS.

Cancer Res. 2013 Jan 1;73(1):341-52. doi: 10.1158/0008-5472.CAN-12-0271. Epub 2012 Jul 25.

41.

Annexin A6 is a scaffold for PKCα to promote EGFR inactivation.

Koese M, Rentero C, Kota BP, Hoque M, Cairns R, Wood P, Vilà de Muga S, Reverter M, Alvarez-Guaita A, Monastyrskaya K, Hughes WE, Swarbrick A, Tebar F, Daly RJ, Enrich C, Grewal T.

Oncogene. 2013 Jun 6;32(23):2858-72. doi: 10.1038/onc.2012.303. Epub 2012 Jul 16.

PMID:
22797061
42.

Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer.

O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Cooper CL, McNeil CM, McFarland A, Nguyen A, Ormandy CJ, Qiu MR, Rabinovich B, Martelotto LG, Vu D, Hannigan GE, Musgrove EA, Christ D, Sutherland RL, Watkins DN, Swarbrick A.

Cancer Res. 2011 Jun 1;71(11):4002-14. doi: 10.1158/0008-5472.CAN-10-3738.

43.

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A.

Nat Med. 2010 Oct;16(10):1134-40. doi: 10.1038/nm.2227. Epub 2010 Sep 26.

44.

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ.

Cancer Res. 2010 Nov 15;70(22):9391-401. doi: 10.1158/0008-5472.CAN-10-0911. Epub 2010 Sep 21.

45.

Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth.

Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, Catena R, Turner V, McDonnell K, Benezra R, Brink R, Swarbrick A, Mittal V.

Cancer Res. 2010 Sep 15;70(18):7273-82. doi: 10.1158/0008-5472.CAN-10-1142. Epub 2010 Aug 31.

46.

Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development.

Nair R, Junankar S, O'Toole S, Shah J, Borowsky AD, Bishop JM, Swarbrick A.

PLoS One. 2010 Aug 3;5(8):e11947. doi: 10.1371/journal.pone.0011947.

47.

The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.

O'Toole SA, Swarbrick A, Sutherland RL.

Expert Opin Ther Targets. 2009 Sep;13(9):1095-103. doi: 10.1517/14728220903130612. Review.

PMID:
19659449
48.

Cell cycle machinery: links with genesis and treatment of breast cancer.

Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL.

Adv Exp Med Biol. 2008;630:189-205. Review.

PMID:
18637492
49.

The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini.

Caldon CE, Swarbrick A, Lee CS, Sutherland RL, Musgrove EA.

Cancer Res. 2008 Apr 15;68(8):3026-36. doi: 10.1158/0008-5472.CAN-07-3079.

50.

Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response.

Swarbrick A, Roy E, Allen T, Bishop JM.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5402-7. doi: 10.1073/pnas.0801505105. Epub 2008 Mar 31.

Supplemental Content

Loading ...
Support Center